An announcement from Anatara Lifesciences Ltd ( (AU:ANR) ) is now available.
Anatara Lifesciences has secured a $400,000 advance on its R&D Tax Incentive refund for FY2025 from a major shareholder group. This funding will support ongoing activities, including the GaRP-IBS trial and the Anti-Obesity Project, without the need for additional capital raising, thus helping the company progress its projects and restore shareholder value after recent mixed trial results.
More about Anatara Lifesciences Ltd
Anatara Lifesciences Ltd is a company focused on developing and commercializing innovative, evidence-based health products targeting unmet needs, particularly in the gastrointestinal tract. They aim to deliver real outcomes for patients while providing strong value for shareholders.
YTD Price Performance: -78.00%
Average Trading Volume: 1,508,797
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$1.17M
See more insights into ANR stock on TipRanks’ Stock Analysis page.